Zimmer Biomet Holdings Inc (ZBH)’s Trend Up, Especially After Today’s Record High Milestone

July 17, 2017 - By Stephen Andrade

The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) reached all time high today, Jul, 17 and still has $141.87 target or 7.00 % above today’s $132.59 share price. This indicates more upside for the $27.47B company. This technical setup was reported by Barchart.com. If the $141.87 PT is reached, the company will be worth $1.92 billion more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

About 943,324 shares traded. Zimmer Biomet Holdings Inc (NYSE:ZBH) has declined 0.44% since July 17, 2016 and is downtrending. It has underperformed by 17.14% the S&P500.

Analysts await Zimmer Biomet Holdings Inc (NYSE:ZBH) to report earnings on July, 27. They expect $2.10 EPS, up 3.96 % or $0.08 from last year’s $2.02 per share. ZBH’s profit will be $435.08 million for 15.78 P/E if the $2.10 EPS becomes a reality. After $2.13 actual EPS reported by Zimmer Biomet Holdings Inc for the previous quarter, Wall Street now forecasts -1.41 % negative EPS growth.

Zimmer Biomet Holdings Inc (NYSE:ZBH) Ratings Coverage

Among 23 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 17 have Buy rating, 2 Sell and 4 Hold. Therefore 74% are positive. Zimmer Biomet Holdings had 44 analyst reports since August 27, 2015 according to SRatingsIntel. Canaccord Genuity maintained the shares of ZBH in report on Friday, September 4 with “Buy” rating. The firm has “Buy” rating given on Wednesday, July 12 by Guggenheim. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) earned “Overweight” rating by Barclays Capital on Friday, April 29. The company was downgraded on Thursday, December 15 by UBS. As per Thursday, January 26, the company rating was maintained by Needham. Zacks downgraded the stock to “Buy” rating in Friday, August 28 report. Guggenheim initiated the shares of ZBH in report on Thursday, June 9 with “Neutral” rating. The rating was maintained by Needham with “Buy” on Friday, January 29. Jefferies maintained Zimmer Biomet Holdings Inc (NYSE:ZBH) on Thursday, June 29 with “Buy” rating. The company was maintained on Tuesday, July 11 by Cantor Fitzgerald.

More notable recent Zimmer Biomet Holdings Inc (NYSE:ZBH) news were published by: Wsj.com which released: “Zimmer Biomet Announces Leadership Transition” on July 11, 2017, also Prnewswire.com with their article: “Zimmer Biomet Holdings Announces Live Audio Webcast and Conference Call of …” published on June 30, 2017, Reuters.com published: “Stryker awarded $248.7 million in patent case against Zimmer” on July 13, 2017. More interesting news about Zimmer Biomet Holdings Inc (NYSE:ZBH) were released by: Bloomberg.com and their article: “Jana Is Said to Hold Zimmer Biomet Talks After Building Stake” published on July 13, 2017 as well as Nasdaq.com‘s news article titled: “Ex-Dividend Reminder: Luminex, Zimmer Biomet Holdings and Pembina Pipeline” with publication date: June 19, 2017.

Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The company has market cap of $27.47 billion. The Company’s products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. It has a 54.28 P/E ratio. The Firm manages its activities through three geographic operating divisions: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.